Interleukin-1beta Inhibition Attenuates Vasculitis in a Mouse Model of Kawasaki Disease.


Journal

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
ISSN: 1347-3409
Titre abrégé: J Nippon Med Sch
Pays: Japan
ID NLM: 100935589

Informations de publication

Date de publication:
2019
Historique:
entrez: 28 5 2019
pubmed: 28 5 2019
medline: 27 11 2019
Statut: ppublish

Résumé

Kawasaki disease (KD), a systemic vasculitis, is suspected to be related to abnormalities in innate immunity. Based on the important role of IL-1 signaling in innate immunity, we investigated the effects of an anti-IL-1β antibody using a Candida albicans water-soluble fraction (CAWS)-induced mouse model of KD. CAWS (0.5 mg/mouse) was injected intraperitoneally into 5-week-old DBA/2 mice on five consecutive days. An anti-Murine IL-1β antibody (01BSUR) was administered at various doses (2.5, 5.0, and 10.0 mg/kg) and time points (2 days before, same day, and 2, 5, 7, and 14 days after CAWS administration). After 4 weeks, vasculitis in the aortic root was investigated histologically. Cytokines including IL-1β, -6, -10, and TNF-α were also measured. Groups administered 01BSUR at all doses showed a significant reduction in the area of vasculitis. In addition, 01BSUR inhibited vasculitis until 7 days after CAWS administration. In the analysis of various time points, the level of IL-6 was lower in all groups compared to the CAWS only group, but the levels of IL-1β, TNFα, and IL-10 were lower when 01BSUR was administered before CAWS. On the other hand, TNFα and IL-10 levels were restored when 01BSUR was administered after CAWS, suggesting that 01BSUR may have additional effects beyond blocking IL-1β signaling. The anti-IL-1β antibody significantly attenuated CAWS-induced vasculitis. The mechanism of inhibiting vasculitis is thought to include inhibition of the IL-1β pathway and additional effects beyond blocking IL-1β signaling.

Sections du résumé

BACKGROUND BACKGROUND
Kawasaki disease (KD), a systemic vasculitis, is suspected to be related to abnormalities in innate immunity. Based on the important role of IL-1 signaling in innate immunity, we investigated the effects of an anti-IL-1β antibody using a Candida albicans water-soluble fraction (CAWS)-induced mouse model of KD.
METHODS METHODS
CAWS (0.5 mg/mouse) was injected intraperitoneally into 5-week-old DBA/2 mice on five consecutive days. An anti-Murine IL-1β antibody (01BSUR) was administered at various doses (2.5, 5.0, and 10.0 mg/kg) and time points (2 days before, same day, and 2, 5, 7, and 14 days after CAWS administration). After 4 weeks, vasculitis in the aortic root was investigated histologically. Cytokines including IL-1β, -6, -10, and TNF-α were also measured.
RESULTS RESULTS
Groups administered 01BSUR at all doses showed a significant reduction in the area of vasculitis. In addition, 01BSUR inhibited vasculitis until 7 days after CAWS administration. In the analysis of various time points, the level of IL-6 was lower in all groups compared to the CAWS only group, but the levels of IL-1β, TNFα, and IL-10 were lower when 01BSUR was administered before CAWS. On the other hand, TNFα and IL-10 levels were restored when 01BSUR was administered after CAWS, suggesting that 01BSUR may have additional effects beyond blocking IL-1β signaling.
CONCLUSIONS CONCLUSIONS
The anti-IL-1β antibody significantly attenuated CAWS-induced vasculitis. The mechanism of inhibiting vasculitis is thought to include inhibition of the IL-1β pathway and additional effects beyond blocking IL-1β signaling.

Identifiants

pubmed: 31130561
doi: 10.1272/jnms.JNMS.2019_86-206
doi:

Substances chimiques

Antibodies 0
Interleukin-1beta 0
Interleukin-6 0
Tumor Necrosis Factor-alpha 0
Interleukin-10 130068-27-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108-116

Auteurs

Yoshiaki Hashimoto (Y)

Department of Pediatrics, Nippon Medical School.

Ryuji Fukazawa (R)

Department of Pediatrics, Nippon Medical School.

Noriko Nagi-Miura (N)

Laboratory for Immunopharmacology of Microbial Products, Tokyo University of Pharmacy and Life Sciences.

Naohito Ohno (N)

Laboratory for Immunopharmacology of Microbial Products, Tokyo University of Pharmacy and Life Sciences.

Nobuko Suzuki (N)

Department of Pediatrics, Nippon Medical School.

Yasuhiro Katsube (Y)

Department of Pediatrics, Nippon Medical School.

Mitsuhiro Kamisago (M)

Department of Pediatrics, Nippon Medical School.

Miharu Akao (M)

Department of Pediatrics, Nippon Medical School.

Makoto Watanabe (M)

Department of Pediatrics, Nippon Medical School.

Koji Hashimoto (K)

Department of Pediatrics, Nippon Medical School.

Kanae Tsuno (K)

Department of Pediatrics, Nippon Medical School.

Ryosuke Matsui (R)

Department of Pediatrics, Nippon Medical School.

Yasuhiko Itoh (Y)

Department of Pediatrics, Nippon Medical School.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH